Across TCGA pan-cancer cohorts, MIR329-2 RNA is linked to patient survival in 3 of 34 cancer types, making it the most broadly survival-associated MIR329-2 data layer compared with 3 for mutation status.

The strongest signal is observed in acute myeloid leukemia (LAML), where higher MIR329-2 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated MIR329-2 expression acts as an unfavorable survival marker, although some lineages such as LAML show a favorable association.

LAML, STAD, and KIRC are the cancer types where MIR329-2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LAML	DFS	Tertile	All	0.820	0.336	.008	36	view →
STAD	DFS	Tertile	All	0.470	0.666	.018	27	view →
KIRC	DFS	Tertile	All	0.198	0.796	.005	18	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: MIR329-2 tumor-vs-normal RNA expression · all MIR329-2 data types